Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 252 participants.
Also called NCT07064525
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 252 participants
- Registry
-
NCT07064525
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT07064525. Randomized; double masking; primary purpose treatment. Start 2024-12-05 (actual); primary completion 2025-12-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
- Condition
- Hypertension (HTN)
- Condition
- NYHA Class III Heart Failure
- Condition
- NYHA Class IV Heart Failure
- Condition
- Diabete Mellitus
- Intervention (Drug)
- SPC1001 Low
- Intervention (Drug)
- SPC5002
- Intervention (Drug)
- SPC5003
- Intervention (Drug)
- SPC5004
- Lead sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Record details
- Record id
cardio:ct-nct07064525- Content hash
430b00fffdf23304785ea4d4323aab25a6edc42fe19a25ea0a84a41bfd1b3650